Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126160762 | 12616076 | 2 | F | 2013 | 20160726 | 20160802 | 20160805 | EXP | IT-009507513-1608ITA000971 | MERCK | 42.00 | YR | F | Y | 0.00000 | 20160805 | OT | IT | IT |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126160762 | 12616076 | 1 | PS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | 800 MG/DAY | 20903 | 800 | MG | CAPSULE | QD | ||||||
126160762 | 12616076 | 2 | SS | PEGINTERFERON ALFA-2B | PEGINTERFERON ALFA-2B | 1 | 100 MICROGRAM PER WEEK | 0 | 100 | UG | POWDER FOR INJECTION | /wk |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126160762 | 12616076 | 1 | Hepatitis C |
126160762 | 12616076 | 2 | Hepatitis C |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126160762 | 12616076 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126160762 | 12616076 | Anaemia | |
126160762 | 12616076 | Hepatitis C |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126160762 | 12616076 | 1 | 201203 | 2012 | 0 | |
126160762 | 12616076 | 2 | 201203 | 2012 | 0 |